WHO ICTRP trial
Therapeutic Effect and Safety Study of Nilotinib plus chemotherapy in de novo…
ChiCTR-ONC-12002469 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-ONC-12002469 |
|---|---|
| Public title | Therapeutic Effect and Safety Study of Nilotinib plus chemotherapy in de novo Ph+ Acute Lymphoblastic Leukemia Patients |
| Scientific title | A Phase ? Study on treatment for Ph+ Acute Lymphoblastic Leukemia |
| Primary sponsor | Hospital of Blood Diseases, Chinese Academy of Medical Sciences |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | II (Phase II study) |
| Countries | China |
| Conditions | De novo Ph+ Acute Lymphoblastic Leukemia |
| Interventions | A group:Nilotinib plus chemotherapy |
| Registration date | Jun 30, 2012 |
| Target size | A group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: